{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:58Z","timestamp":1786119358860,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1097\/mbc.0b013e32832da1e3","type":"journal-article","created":{"date-parts":[[2009,10,29]],"date-time":"2009-10-29T03:17:35Z","timestamp":1256786255000},"page":"627-634","source":"Crossref","is-referenced-by-count":39,"title":["The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity"],"prefix":"10.1097","volume":"20","author":[{"given":"Cinara L","family":"Echart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Graziadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Somaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura I","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawed","family":"Fareed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Iacobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210203","first-page":"300","article-title":"Resting plasma fibrinolytic activity and fibrinolytic potential in peripheral vascular disease","volume":"29","author":"Earnshaw","year":"1998","journal-title":"J Cardiovasc Surg"},{"key":"R2-3-20210203","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1160\/TH06-12-0715","article-title":"Fibrin clot structure in patiens with end-stage renal disease","volume":"98","author":"Sj\u00f8land","year":"2007","journal-title":"Thromb Haemost"},{"key":"R3-3-20210203","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1160\/TH07-10-0640","article-title":"Factor VII-activating protease (FSAP): vascular functions and role in atherosclerosis","volume":"99","author":"Kanse","year":"2008","journal-title":"Thromb Haemost"},{"key":"R4-3-20210203","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/sj.bmt.1702624","article-title":"Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study","volume":"26","author":"Tanikawa","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R5-3-20210203","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-2007-976173","article-title":"Hepatic venous-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide","volume":"33","author":"Ho","year":"2007","journal-title":"Semin Thromb Haemost"},{"key":"R6-3-20210203","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00001721-199710000-00001","article-title":"Veno-occlusive disease of the liver after bone marrow transplantation: is hypercoagulability really part of the problem?","volume":"8","author":"Korte","year":"1997","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R7-3-20210203","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1399-3046.2006.00612.x","article-title":"Favorable response of pediatric stem cell recipients to human protein C concentrate substitution for veno-occlusive disease","volume":"11","author":"Eber","year":"2007","journal-title":"Pediatr Transplant"},{"key":"R8-3-20210203","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/1024533031000084231","article-title":"Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF)","volume":"8","author":"Kaleelrahman","year":"2003","journal-title":"Hematology"},{"key":"R9-3-20210203","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ajh.20958","article-title":"Hepatic veno-occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Mori","year":"2007","journal-title":"Am J Hematol"},{"key":"R10-3-20210203","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.V89.5.1501","article-title":"Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients","volume":"89","author":"Bearman","year":"1997","journal-title":"Blood"},{"key":"R11-3-20210203","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/sj.leu.2403004","article-title":"Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells","volume":"17","author":"Falanga","year":"2003","journal-title":"Leukemia"},{"key":"R12-3-20210203","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.V100.1.334","article-title":"Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide","volume":"100","author":"Eissner","year":"2002","journal-title":"Blood"},{"key":"R13-3-20210203","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00003495-199345020-00007","article-title":"Defibrotide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders","volume":"45","author":"Palmer","year":"1993","journal-title":"Drugs"},{"key":"R14-3-20210203","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000046590","article-title":"Hepatic veno-occlusive disease following hematopoietic stem cell transplantation","volume":"106","author":"Richardson","year":"2001","journal-title":"Acta Haematol"},{"key":"R15-3-20210203","first-page":"737","article-title":"Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population","volume":"92","author":"Richardson","year":"1998","journal-title":"Blood"},{"key":"R16-3-20210203","first-page":"1122","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study","volume":"111","author":"Chopra","year":"2000","journal-title":"Br J Haematol"},{"key":"R18-3-20210203","first-page":"53","article-title":"Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues","volume":"25","author":"Parry","year":"2001","journal-title":"TIBS"},{"key":"R19-3-20210203","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0021-9258(19)85983-5","article-title":"Kinetics of activation of human plasminogen by different activator species at Ph 7.4 and 37 Degrees C","volume":"255","author":"Wohl","year":"1980","journal-title":"J Biol Chem"},{"key":"R20-3-20210203","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0003-9861(91)90090-6","article-title":"Plasmin binding to the plasminogen receptor enhances catalytic efficiency and activates the receptor for subsequent ligand binding","volume":"286","author":"Gonzalez-Gronow","year":"1991","journal-title":"Arch Biochem Biophys"},{"key":"R21-3-20210203","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1538-7836.2004.00816.x","article-title":"A proposed reference method for plasminogen activators that enables calculation of enzyme activates in SI units","volume":"2","author":"Longstaff","year":"2004","journal-title":"J Thromb Haemost"},{"key":"R22-3-20210203","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0049-3848(00)00329-7","article-title":"Inhibition of plasmin activity by sulfated polyvinylalcohol-acrylate copolymers","volume":"100","author":"V\u00f6r\u00f6s","year":"2000","journal-title":"Thromb Res"},{"key":"R23-3-20210203","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1042\/bj2600609","article-title":"Effects of penicillins and 6-aminohexanoic acid on the kinetics of human plasmin","volume":"260","author":"Higazi","year":"1989","journal-title":"Biochem J"},{"key":"R24-3-20210203","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1432-1033.1980.tb04461.x","article-title":"Studies on the lysine-binding sites of human plasminogen. The effect of ligand on the binding of lysine analogs to plasminogen","volume":"104","author":"Winn","year":"1980","journal-title":"Eur J Biochem"},{"key":"R25-3-20210203","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1432-1033.1975.tb02472.x","article-title":"A new method of isolation and some properties of the heavy chain of human plasmin","volume":"59","author":"Rickli","year":"1975","journal-title":"Eur J Biochem"},{"key":"R26-3-20210203","doi-asserted-by":"crossref","first-page":"26774","DOI":"10.1074\/jbc.C600171200","article-title":"Binding of the COOH-terminal lysine residues of streptokinase to plasmin(ogen) kringles enhances formation of the streptokinase\u2022Plasmin(ogen) catalytic complexes","volume":"281","author":"Panizzi","year":"2006","journal-title":"J Biol Chem"},{"key":"R27-3-20210203","doi-asserted-by":"crossref","first-page":"5395","DOI":"10.1016\/S0021-9258(17)30384-8","article-title":"The effect of \u03b1-\u03c9-amino acids on human plasminogen structure and activation","volume":"253","author":"Violand","year":"1978","journal-title":"J Biol Chem"},{"key":"R28-3-20210203","first-page":"46","article-title":"The kringle domains of human plasminogen","volume":"212","author":"Castellino","year":"1997","journal-title":"Ciba Found Symp"},{"key":"R29-3-20210203","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1016\/S0021-9258(18)32614-0","article-title":"The binding of human plasminogen to fibrin and fibrinogen","volume":"258","author":"Lucas","year":"1983","journal-title":"J Biol Chem"},{"key":"R30-3-20210203","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1021\/bi00334a031","article-title":"Quantitative characterization of the binding of plasminogen to intact fibrin clots, lysine-sepharose, and fibrin cleaved by plasmin","volume":"24","author":"Bok","year":"1985","journal-title":"Biochemistry"},{"key":"R31-3-20210203","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1042\/bj2180119","article-title":"Interaction of plasmin with endothelial cells","volume":"218","author":"Bauer","year":"1986","journal-title":"Biochem J"},{"key":"R32-3-20210203","doi-asserted-by":"crossref","first-page":"11656","DOI":"10.1016\/S0021-9258(18)67293-X","article-title":"Binding of plasminogen to cultured human endothelial cell","volume":"261","author":"Hajjar","year":"1986","journal-title":"J Biol Chem"},{"key":"R33-3-20210203","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1055\/s-0038-1646369","article-title":"Cellular regulation of fibrinolysis","volume":"66","author":"Plow","year":"1991","journal-title":"Thromb Haemost"},{"key":"R34-3-20210203","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2174\/092986708783955455","article-title":"Frinolysis: the key to new pathogenetic mechanisms","volume":"15","author":"Zorio","year":"2008","journal-title":"Curr Med Chem"},{"key":"R35-3-20210203","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1182\/blood-2005-08-3452","article-title":"Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein","volume":"107","author":"Lee","year":"2006","journal-title":"Blood"},{"key":"R36-3-20210203","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1055\/s-0038-1648158","article-title":"Stimulation of plasmin activity by aspirin","volume":"65","author":"Milwidsky","year":"1991","journal-title":"Thromb Haemost"},{"key":"R37-3-20210203","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1042\/bj2820863","article-title":"Stimulation of plasmin activity by oleic acid","volume":"282","author":"Higazi","year":"1992","journal-title":"Biochem J"},{"key":"R38-3-20210203","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0145-2126(95)00009-D","article-title":"Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1","volume":"19","author":"Higashigawa","year":"1995","journal-title":"Leuk Res"},{"key":"R39-3-20210203","first-page":"3535","article-title":"No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation","volume":"27","author":"Hagglund","year":"1995","journal-title":"Transplant Proc"},{"key":"R40-3-20210203","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/sj.bmt.1702069","article-title":"Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation","volume":"24","author":"Schriber","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"R41-3-20210203","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/sj.bmt.1701654","article-title":"Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD)","volume":"23","author":"Kulkarni","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"R42-3-20210203","first-page":"9","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation:update on defibrotide and other current investigational therapies.","volume":"1-","author":"Ho","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R43-3-20210203","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1055\/s-0037-1616127","article-title":"Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit","volume":"86","author":"Marder","year":"2001","journal-title":"Thromb Haemost"},{"key":"R44-3-20210203","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2002-08-2546","article-title":"Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage","volume":"101","author":"Steward","year":"2003","journal-title":"Blood"},{"key":"R45-3-20210203","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1538-7836.2008.02969.x","article-title":"A first-in-human phase I trial of locally-delivered human plasmin for hemodialysis graft occlusion","volume":"6","author":"Shlansky-Goldberg","year":"2008","journal-title":"J Thromb Haemost"},{"key":"R46-3-20210203","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","article-title":"Multiinstitutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"}],"container-title":["Blood Coagulation & Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001721-200912000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:03:20Z","timestamp":1786039400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001721-200912000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0b013e32832da1e3","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}